Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.

Yuki NemotoHiroki IshiharaKazutaka NakamuraHidekazu TachibanaHironori FukudaKazuhiko YoshidaHirohito KobayashiJunpei IizukaHiroaki ShimmuraYasunobu HashimotoKazunari TanabeTsunenori KondoToshio Takagi

Published in: International urology and nephrology (2021)

The efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab were comparable between elderly and young patients. Thus, chronological age alone should not be a contraindication in the use of ICIs for mRCC.

Keyphrases

end stage renal disease
metastatic renal cell carcinoma
ejection fraction
newly diagnosed
middle aged
peritoneal dialysis
randomized controlled trial
open label
patient reported outcomes
community dwelling